| Literature DB >> 26289640 |
Sebastian Fuchs1, Anne Rensing-Ehl2, Ulrich Pannicke3, Myriam R Lorenz3, Paul Fisch4, Yogesh Jeelall5, Jan Rohr6, Carsten Speckmann6, Thomas Vraetz7, Susan Farmand8, Annette Schmitt-Graeff4, Marcus Krüger7, Brigitte Strahm7, Philipp Henneke6, Anselm Enders5, Keisuke Horikawa5, Christopher Goodnow5, Klaus Schwarz9, Stephan Ehl6.
Abstract
Omenn syndrome (OS) is a severe immunodeficiency associated with erythroderma, lymphoproliferation, elevated IgE, and hyperactive oligoclonal T cells. A restricted T-cell repertoire caused by defective thymic T-cell development and selection, lymphopenia with homeostatic proliferation, and lack of regulatory T cells are considered key factors in OS pathogenesis. We report 2 siblings presenting with cytomegalovirus (CMV) and Pneumocystis jirovecii infections and recurrent sepsis; one developed all clinical features of OS. Both carried homozygous germline mutations in CARD11 (p.Cys150*), impairing NF-κB signaling and IL-2 production. A somatic second-site mutation reverting the stop codon to a missense mutation (p.Cys150Leu) was detected in tissue-infiltrating T cells of the OS patient. Expression of p.Cys150Leu in CARD11-deficient T cells largely reconstituted NF-κB signaling. The reversion likely occurred in a prethymic T-cell precursor, leading to a chimeric T-cell repertoire. We speculate that in our patient the functional advantage of the revertant T cells in the context of persistent CMV infection, combined with lack of regulatory T cells, may have been sufficient to favor OS. This first observation of OS in a patient with a T-cell activation defect suggests that severely defective T-cell development or homeostatic proliferation in a lymphopenic environment are not required for this severe immunopathology.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26289640 PMCID: PMC4654427 DOI: 10.1182/blood-2015-03-631374
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113